Recordati S.p.A. - Recordati sells its holding in Confarma

Press Releases

Recordati sells its holding in Confarma

Milan, 20 December 2006 - Recordati announced that it has sold its 3.13% holding in Confarma, a company owned by a number of pharmaceutical companies which in turn owns 60% of Farmafactoring S.p.A., to FF Holding S.p.A., a company controlled by the funds managed by Apax Partners Worldwide Ltd. Together with Recordati the majority of Confarma's shareholders decided to sell their stakes. Recordati realized a capital gain of around € 5 million from the operation (the book value of this investment was very low). The proceeds from the sale were cashed when the agreement was signed.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), dedicated to the research, development, manufacturing and marketing of pharmaceuticals, with headquarters in Milan, Italy, operations in the main European countries, and a total staff of over 2,000. A European field force of over 1,000 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas in which its research team has proven scientific competence and a track record of discovery and development of original drugs, the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product. Consolidated revenue for 2005 was € 576.1 million, operating income was € 111.1 million and net income was € 64.5 million.

For further information:

Recordati website: www.recordati.com

Investor Relations
Marianne Tatschke
(39)0248787393
e-mail: inver@recordati.it

Media Relations
Claudio Rossetti (Echo Comunicazione d’Impresa)
(39)02 62694736
e-mail: crossetti@echocom.it

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements.
All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

		Home Site Map Alert Service Versione Italiana
About us Pharmaceutical operations Rare diseases Investors Corporate Governance Publications Join Us Contacts
Home Investors Press Releases 2006 Print Page Bookmark Page
Shareholder information Recordati at a glance Key Financial Data Recordati Share Press Releases 2008 2007 2006 2005 2004 2003 2002 2001 2000 Company Presentations Annual and Interim Reports Calendar Analyst Coverage Contacts	Press Releases Recordati sells its holding in Confarma Milan, 20 December 2006 - Recordati announced that it has sold its 3.13% holding in Confarma, a company owned by a number of pharmaceutical companies which in turn owns 60% of Farmafactoring S.p.A., to FF Holding S.p.A., a company controlled by the funds managed by Apax Partners Worldwide Ltd. Together with Recordati the majority of Confarma's shareholders decided to sell their stakes. Recordati realized a capital gain of around € 5 million from the operation (the book value of this investment was very low). The proceeds from the sale were cashed when the agreement was signed. Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), dedicated to the research, development, manufacturing and marketing of pharmaceuticals, with headquarters in Milan, Italy, operations in the main European countries, and a total staff of over 2,000. A European field force of over 1,000 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas in which its research team has proven scientific competence and a track record of discovery and development of original drugs, the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product. Consolidated revenue for 2005 was € 576.1 million, operating income was € 111.1 million and net income was € 64.5 million. For further information: Recordati website: www.recordati.com Investor Relations Marianne Tatschke (39)0248787393 e-mail: inver@recordati.it Media Relations Claudio Rossetti (Echo Comunicazione d’Impresa) (39)02 62694736 e-mail: crossetti@echocom.it Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.